Edgewise Therapeutics: Advancing Treatments for Rare Muscle Disorders

Edgewise Therapeutics, Inc. is a biopharmaceutical company at the forefront of developing new therapies for severe and rare muscle disorders. As a clinical-stage company, Edgewise is deeply committed to discovering, developing, and bringing to market innovative treatments for conditions where current options are limited or nonexistent.

Focused Mission and Innovative Approach

The company’s mission centers on addressing significant unmet medical needs, particularly for patients living with rare neuromuscular and cardiac diseases. Edgewise Therapeutics utilizes a proprietary drug discovery platform designed to identify small molecule precision medicines that target and regulate essential proteins within muscle tissue. This advanced platform relies on custom-built systems that measure muscle function at the organ level, providing unique insights that drive the development of highly targeted therapies.

Research and Development

Edgewise’s scientific strategy sets it apart in the biopharmaceutical landscape. By focusing on whole organ extracts and real-world measurements of muscle performance, the company increases the likelihood of developing effective medicines with real impact on patient health. This method supports the identification and optimization of compounds that precisely modulate muscle function, a crucial factor in treating complex neuromuscular conditions.

Company Background and Leadership

Founded in 2017 by Badreddin Edris, Alan Russel, and Peter A. Thompson, Edgewise Therapeutics is headquartered in Boulder, Colorado. Since its inception, the company has built a team of experts with deep experience in drug development and muscle biology, further strengthening its ability to move new therapies from the laboratory to clinical trials.

Financial Overview

As of the most recent update, Edgewise Therapeutics trades at $12.96 per share, reflecting a 2.78% increase for the day. The stock has fluctuated within a range of $12.67 to $13.01 during the day, and its 52-week performance has ranged from $10.60 to $38.12 per share. The company’s market capitalization stands at approximately $1.33 billion, with 105.2 million shares outstanding and a public float of 77.09 million shares.

Looking Ahead

Edgewise Therapeutics continues to push forward in its mission to develop life-changing treatments for patients suffering from rare muscle diseases. With its innovative research platform, dedicated leadership, and robust financial backing, the company is well-positioned to make meaningful advances in the field of rare disease therapeutics.